scholarly journals 0356 : Disseminated arterial calcification and enhanced myogenic response are associated with Abcc6 deficiency in a mouse model of pseudoxanthoma elasticum

2015 ◽  
Vol 7 (2) ◽  
pp. 188
Author(s):  
Gilles Kauffenstein ◽  
Anne Pizard ◽  
Yannick Le Corre ◽  
Emilie Vessières ◽  
Linda Grimaud ◽  
...  
2014 ◽  
Vol 7 (7) ◽  
pp. 811-822 ◽  
Author(s):  
A. Apschner ◽  
L. F. A. Huitema ◽  
B. Ponsioen ◽  
J. Peterson-Maduro ◽  
S. Schulte-Merker

2020 ◽  
Vol 292 ◽  
pp. 37-41 ◽  
Author(s):  
Jonas W. Bartstra ◽  
Pim A. de Jong ◽  
Guido Kranenburg ◽  
Jelmer M. Wolterink ◽  
Ivana Isgum ◽  
...  

2010 ◽  
Vol 298 (2) ◽  
pp. F285-F292 ◽  
Author(s):  
Samira C. Grifoni ◽  
Rumbidzayi Chiposi ◽  
Susan E. McKey ◽  
Michael J. Ryan ◽  
Heather A. Drummond

Renal blood flow (RBF) autoregulation is mediated by at least two mechanisms, the fast acting myogenic response (∼5 s) and slow acting tubuloglomerular feedback (TGF; ∼25 s). Previous studies suggest epithelial Na+ channel (ENaC) family proteins, β-ENaC in particular, mediate myogenic constriction in isolated renal interlobar arteries. However, it is unknown whether β-ENaC-mediated myogenic constriction contributes to RBF autoregulation in vivo. Therefore, the goal of this investigation was to determine whether the myogenic mediated RBF autoregulation is inhibited in a mouse model of reduced β-ENaC (m/m). To address this goal, we evaluated the temporal response of RBF and renal vascular resistance (RVR) to a 2-min step increase in mean arterial pressure (MAP). Pressure-induced changes in RBF and RVR at 0–5, 6–25, and 110–120 s after step increase in MAP were used to assess the contribution of myogenic and TGF mechanisms and steady-state autoregulation, respectively. The rate of the initial increase in RVR, attributed to the myogenic mechanism, was reduced by ∼50% in m/m mice, indicating the speed of the myogenic response was inhibited. Steady-state autoregulation was similar between β-ENaC +/+ and m/m mice. Although the rate of the secondary increase in RVR, attributed to TGF, was similar in β-ENaC +/+ and m/m mice, however, it occurred over a longer period (+10 s), which may have allowed TGF to compensate for a loss in myogenic autoregulation. Our findings suggest β-ENaC is an important mediator of renal myogenic constriction-mediated RBF autoregulation in vivo.


2012 ◽  
Vol 90 (1) ◽  
pp. 25-39 ◽  
Author(s):  
Yvonne Nitschke ◽  
Geneviève Baujat ◽  
Ulrike Botschen ◽  
Tanja Wittkampf ◽  
Marcel du Moulin ◽  
...  

Biomedicines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1895
Author(s):  
Max Jonathan Stumpf ◽  
Nadjib Schahab ◽  
Georg Nickenig ◽  
Dirk Skowasch ◽  
Christian Alexander Schaefer

Pseudoxanthoma elasticum (PXE) is a rare, genetic, metabolic disease with an estimated prevalence of between 1 per 25,000 and 56,000. Its main hallmarks are characteristic skin lesions, development of choroidal neovascularization, and early-onset arterial calcification accompanied by a severe reduction in quality-of-life. Underlying the pathology are recessively transmitted pathogenic variants of the ABCC6 gene, which results in a deficiency of ABCC6 protein. This results in reduced levels of peripheral pyrophosphate, a strong inhibitor of peripheral calcification, but also dysregulation of blood lipids. Although various treatment options have emerged during the last 20 years, many are either already outdated or not yet ready to be applied generally. Clinical physicians often are left stranded while patients suffer from the consequences of outdated therapies, or feel unrecognized by their attending doctors who may feel uncertain about using new therapeutic approaches or not even know about them. In this review, we summarize the broad spectrum of treatment options for PXE, focusing on currently available clinical options, the latest research and development, and future perspectives.


Sign in / Sign up

Export Citation Format

Share Document